Physicians Interactive acquires Univadis portal
pharmafile | October 22, 2015 | News story | Medical Communications, Sales and Marketing | Merck, Physicians Interactive, Univadis
Digital marketing firm Physicians Interactive (PI) has acquired the Univadis medical information platform, in a move which it says creates the largest online healthcare professional network (HPC).
Both PI and Univadis were previously full-owned subsidiaries of Merck, but have now moved to combine their networks to take their total membership to more than three million users, communicating in over 20 languages, across 63 specialties and in more than 90 countries.
Univadis provides a suite of clinically-relevant resources for HCPs, including medical news, conference reports, references, textbooks and online education modules, which Merck believes, when combined with PI, will provide valuable and credible medical content and for the life sciences companies, payers, and providers who leverage these digital properties to drive education and awareness of new medical and digital innovations aimed at improving health outcomes.
“Adding Univadis to the Physicians Interactive brand underscores our mission to advance health engagement across the entire spectrum, as well as across the globe,” says Donato Tramuto, chairman and CEO of Physicians Interactive.
“There is a transformation underway in healthcare, one that requires a fresh, integrated approach grounded in proven digital strategies. With the expanded reach and rich medical content this acquisition offers, we are even better positioned to provide the end-to-end solutions our commercial partners need to deeply engage healthcare professionals – resulting in greater awareness and better health outcomes.”
This acquisition also positions PI as a global digital partner for its clients looking to further engage health care professionals through digital channels – offering centrally managed, multinational campaigns featuring localised content.
Today these international markets include France, Spain, Italy, the United Kingdom and the United States; continued expansion into dozens of markets around the world is planned over the next three years.
Joel Levy
Related Content
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …
